Brian Zeno, MD
Pulmonary Disease · Columbus, OHNPI 1033149596
Payments from drug & device makers
Across 242 payments — averaging $11,967 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$674K
- Novartis$417K
- GSK$407K
- Hoffmann-la Roche Limited$338K
- Chiesi USA, Inc.$300K
- Mylan Specialty L.p.$277K
- plus $483K from 9 others
Across 4 payments — averaging $24,212 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$97K
What the payments were for
- Travel & lodging$1,09119%
- Food & beverage$69112%
- Education$4,00069%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 7 | $673,573 |
| Novartis | 4 | $417,416 |
| GSK | 89 | $407,417 |
| Hoffmann-la Roche Limited | 5 | $337,970 |
| Chiesi USA, Inc. | 60 | $300,492 |
| Mylan Specialty L.p. | 26 | $276,612 |
| AstraZeneca | 15 | $222,825 |
| Genentech, Inc. | 8 | $129,485 |
| Regeneron | 7 | $84,743 |
| Pfizer | 7 | $29,313 |
| Merck | 1 | $10,500 |
| Intuitive Surgical | 10 | $5,363 |
| Johnson & Johnson | 1 | $124 |
| Boston Scientific | 1 | $120 |
| Pulmonx Corporation | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,896,070 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Columbus
- Edward CordascoColumbus$8M
- Roy St JohnColumbus$1.9M
- Nitin BhattColumbus$876K
- Matthew ExlineColumbus$386K
- Christian GhattasColumbus$286K
- Alberto ReveloColumbus$232K
- Derrick HermanColumbus$213K
- James FaganColumbus$179K
- Todd AstorColumbus$102K
- Lynn FussnerColumbus$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.